| scholarly article | Q13442814 |
| P50 | author | Srdan Verstovsek | Q64026418 |
| Ayalew Tefferi | Q66370740 | ||
| P2093 | author name string | Nicolaus Kröger | |
| Tiziano Barbui | |||
| Alessandro M Vannucchi | |||
| Animesh Pardanani | |||
| Juergen Thiele | |||
| Jason Gotlib | |||
| Claire Harrison | |||
| Francisco Cervantes | |||
| Giovanni Barosi | |||
| Ronald Hoffman | |||
| Ruben Mesa | |||
| Francesco Passamonti | |||
| Heinz Gisslinger | |||
| Brigitte Dupriez | |||
| P2860 | cites work | Pomalidomide is active in the treatment of anemia associated with myelofibrosis | Q33385644 |
| Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 | ||
| A phase-2 trial of low-dose pomalidomide in myelofibrosis | Q33392689 | ||
| Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis | Q33393587 | ||
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies | Q34158356 | ||
| Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. | Q36003480 | ||
| International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). | Q36468734 | ||
| Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs | Q36915139 | ||
| Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. | Q37412790 | ||
| Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management | Q38076672 | ||
| The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. | Q40463923 | ||
| Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 | ||
| Report of an international working group to standardize response criteria for myelodysplastic syndromes. | Q40737646 | ||
| Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation | Q43265365 | ||
| Improving survival trends in primary myelofibrosis: an international study. | Q53126695 | ||
| What are RBC-transfusion-dependence and -independence? | Q59620003 | ||
| Thrombosis in primary myelofibrosis: incidence and risk factors | Q61050096 | ||
| Allogeneic hematopoietic stem cell transplantation for myelofibrosis | Q73812277 | ||
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 | ||
| Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment | Q80866784 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myelofibrosis | Q1752571 |
| P304 | page(s) | 1395-1398 | |
| P577 | publication date | 2013-07-09 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report | |
| P478 | volume | 122 |
| Q38945717 | A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence |
| Q90273548 | A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients |
| Q33434284 | A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis |
| Q36708975 | A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis |
| Q37740928 | A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence |
| Q100525829 | ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden |
| Q64906544 | Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis. |
| Q92509180 | Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper |
| Q49929057 | Advancing a field by building consortia: The example of the European LeukemiaNet |
| Q33430113 | Alleviating anemia and thrombocytopenia in myelofibrosis patients |
| Q60710884 | Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning |
| Q39048645 | An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults |
| Q52564132 | Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α. |
| Q45236578 | Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis |
| Q49490860 | Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation |
| Q90568323 | Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) |
| Q38242725 | Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) |
| Q96949235 | Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy |
| Q41084893 | Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study |
| Q42760638 | Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners? |
| Q41048116 | Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. |
| Q26996258 | Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis |
| Q33423956 | Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. |
| Q38287012 | Definition and management of ruxolitinib treatment failure in myelofibrosis |
| Q48008083 | Developmental Therapeutics in Myeloproliferative Neoplasms |
| Q37679175 | Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. |
| Q36169641 | Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment |
| Q49968459 | Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis |
| Q33441917 | Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study |
| Q33419957 | Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. |
| Q52721155 | Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. |
| Q59135610 | Genetic predictors of response to specific drugs in primary myelofibrosis |
| Q26778326 | Guidelines for the management of myeloproliferative neoplasms |
| Q54357496 | High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. |
| Q89319548 | How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis? |
| Q88287987 | How to define treatment failure for JAK inhibitors |
| Q49629652 | Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms |
| Q96767821 | Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies |
| Q38629189 | Immunotherapy based approaches in myelofibrosis |
| Q93091989 | Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib |
| Q89777328 | Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy |
| Q38926187 | Improving Spleen Volume Estimation Via Computer-assisted Segmentation on Clinically Acquired CT Scans |
| Q38691019 | Investigational Janus kinase inhibitors in development for myelofibrosis |
| Q40261233 | Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era? |
| Q50131520 | JAK inhibition and symptom control in myeloproliferative neoplasms. |
| Q41160178 | JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells |
| Q38684435 | JAK2 inhibitors for myeloproliferative neoplasms: what is next? |
| Q40854467 | JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. |
| Q63728935 | JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation |
| Q38195778 | Jak-2 positive myeloproliferative neoplasms |
| Q33442629 | Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study |
| Q36816733 | Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival |
| Q91646850 | Lessons Learned in the Development of a Computable Phenotype for Response in Myeloproliferative Neoplasms |
| Q92147338 | Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis |
| Q51733623 | Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. |
| Q41765106 | Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis |
| Q33422565 | Long-term results of prednisone treatment for the anemia of myelofibrosis. |
| Q88800685 | Management of Myelofibrosis-Related Cytopenias |
| Q90547544 | Management of myelofibrosis after ruxolitinib failure |
| Q90029058 | Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF |
| Q41980585 | Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis |
| Q54998956 | Momelotinib therapy for myelofibrosis: a 7-year follow-up. |
| Q47671095 | Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial |
| Q59329603 | Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea |
| Q38989215 | Myelofibrosis: an update on drug therapy in 2016. |
| Q40795436 | Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls |
| Q35188877 | Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia |
| Q90622530 | Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis |
| Q37272164 | Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. |
| Q33440361 | Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial |
| Q51742255 | Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. |
| Q90064075 | Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group |
| Q39069010 | Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis |
| Q90397526 | Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? |
| Q38254893 | Quality of life in MPN comes of age as a therapeutic target |
| Q91763860 | RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA |
| Q44993985 | Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. |
| Q38341625 | Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors |
| Q33421596 | Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial |
| Q54319890 | Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. |
| Q38814941 | Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients |
| Q26738514 | Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned |
| Q38938939 | Ruxolitinib dose management as a key to long-term treatment success |
| Q33437121 | Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. |
| Q49993088 | SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis |
| Q63728939 | Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis |
| Q51048904 | Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. |
| Q33415731 | Safety evaluation of ruxolitinib for treating myelofibrosis |
| Q48371991 | Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation |
| Q38567540 | Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis |
| Q39601719 | Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. |
| Q50042813 | Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response |
| Q33432158 | The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy |
| Q40197045 | The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis |
| Q36091279 | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| Q53084678 | The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading. |
| Q58580502 | The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase 2 study SAKK 33/14 |
| Q35988523 | Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase |
| Q91942151 | Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice |
| Q39349869 | Treatment of Myelofibrosis: Old and New Strategies |
| Q52640385 | Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis. |
| Q50453985 | Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. |
| Q40085126 | Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. |
| Q86478957 | [Chinese expert consensus on the diagnosis and treatment of primary myelofibrosis （2015)] |
Search more.